# A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06618287/  
OnCo record `nct06618287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Osimertinib, Pembrolizumab, Nivolumab and PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06618287 by Bristol-Myers Squibb, with 416 participants planned, started 2025-02-04 and due to reach its primary completion in 2031-02-26. Interventions recorded: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab and Pumitamig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06618287
- Phase: 1/2
- Setting: A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT06618287: https://clinicaltrials.gov/study/NCT06618287

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06618287.json